With this financing and outstanding syndicate of investors, Arrakis will leap to the next stage of realizing our vision of creating a new class of medicines with RNA-targeted small molecules, or rSMs.

Company Information

Company Status

Private & Independent

Industry

Biopharmaceutical

Mailing Address

830 Winter St.
Waltham, MA 02451
USA

Phone

Undisclosed

Website

www.arrakistx.com

Email Address

[email protected]

Overview

The therapeutic potential of the human transcriptome, the set of all RNAs transcribed from DNA, remains largely unexplored. By harnessing new insights into RNA structure and dynamics, Arrakis is opening the transcriptome to therapy by small-molecule medicines to treat patients not cured by today's medicines.

Profile

Social Media

Arrakis Therapeutics Company Twitter Account

Company News

Facebook

YouTube

Management Team

Title

Name

Email & Social

Chief Executive Officer

Michael Gilman

Chief Scientific Officer

Russell Petter

Vice President

James Barsoum

Vice President

Gnanasambandam Kumaravel

VP - Bus. Development

Daniel Koerwer

VP - Operations

Heather Lounsbury

Browse more venture capital transactions:

Prev: 4/19/2019: Phantom AI venture capital transaction
Next: 4/19/2019: Viome venture capital transaction

Share this article

About Database of VC Transactions

We do our best to report on tech company VC transactions. VC investment data records on this site are sourced from news reports and company announcements. The information comes to us via our partnership with VentureDeal.com, an affiliated venture.

Additional Resources for Entrepreneurs

Lists of Venture Capital and Private Equity Firms

Franchise Opportunities

Contributors

Business Glossary